Last Price
71.04
Today's Change
-1.87 (2.56%)
Day's Change
70.19 - 73.22
Trading Volume
1,723,418
Exchange: NASDAQ Global Select NASDAQ Global Select
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Mr. William H. Lewis J.D., M.B.A. Mr. William H. Lewis J.D., M.B.A.
Full Time Employees: 912 912
IPO Date: 2000-06-01 2000-06-01
CIK: 0001104506 0001104506
ISIN: US4576693075 US4576693075
CUSIP: 457669307 457669307
Beta: 1.11 1.11
Last Dividend: 0.00 0.00
Dcf Diff: 3.63 3.63
Dcf: 25.32 25.32
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.